Trivalent Influenza Vaccine
Not recommended VaccinesUnrestrictedNot applicable line
Annual vaccination for Aboriginal and Torres Strait Islander children aged 6 months to 5 years to prevent influenza infection and reduce disease severity.
1
Submissions
1 resub
2014–14
On the record
—
ICER range
Not modelled
Cost basis
Decisions on record
- Meeting Jul 2018 Not recommended Prevention of seasonal influenza
- Meeting Jul 2014 Recommended Office of Health Protection, Department of Heath Change to listing (Minor submission) Influenza Extension of the National Immunisation Program (NIP) schedule to include trivalent influenza vaccine (TIV) for all Aboriginal and Torres Strait Islander children aged between 6 months and 5 years.
Access path
- Jul 2014Recommended
vs medically at risk cohort (children with underlying medical…
- PBS listing · Unrestricted
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
5.1 Out of session between the March 2014 and July 2014 PBAC meetings, the Committee recommended extending the availability of trivalent influenza vaccine under the National Immunisation Program to include annual vaccination for all Aboriginal and Torres Strait Islander children aged 6 months to 5 years.PSD · Jul 2014
5.2 The PBAC agreed that the cost-effectiveness of vaccination in this population was likely to be similar to the cost-effectiveness of vaccination in the already funded “medically at risk cohort”.PSD · Jul 2014
Economic analysis
4.3 A formal economic analysis was not provided in the submission.PSD · Jul 2014
4.4 Based on evidence that Indigenous children aged 6 months to 5 years have higher disease burden than the funded “medically at risk cohort” and comparable vaccinePSD · Jul 2014
Cost-effectiveness
No formal economic analysis was provided; cost-effectiveness was inferred by comparison with funded medically at-risk cohort rather than by explicit ICER calculation.
ICER uncertainIndirect comparisonCost-effectiveness accepted
Decision context
PopulationAboriginal and Torres Strait Islander children aged 6 months to 5 years.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2014 | Recommended | medically at risk cohort (children with underlying medical conditions already funded under NIP) | — | Other · Other |
Similar precedents
Inactivated Quadrivalent Influenza Vaccine (Split Virion)78%Quadrivalent Influenza Vaccine (Split Virion, Inactivated)76%Quadrivalent Influenza Vaccine75%Inactivated Trivalent Influenza Vaccine (Split Virion)74%Influenza Vaccine, Injection72%Cell-Cultured Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated)71%Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated, Cell-Based)70%Inactivated Trivalent Influenza Vaccine (Surface Antigen), Adjuvanted69%